NASDAQ:BLRX BioLineRx (BLRX) Stock Price, News & Analysis $1.16 +0.01 (+0.43%) Closing price 03:59 PM EasternExtended Trading$1.15 -0.01 (-0.61%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About BioLineRx Stock (NASDAQ:BLRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioLineRx alerts:Sign Up Key Stats Today's Range$1.11▼$1.2950-Day Range$1.15▼$2.6052-Week Range$1.11▼$3.95Volume32,425 shsAverage Volume25,888 shsMarket Capitalization$5.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview BioLineRx Ltd. is an Israel-based biopharmaceutical company that develops therapies for cancer and other serious diseases. Founded in 2003, the company advances drug candidates through clinical development and works with commercial and development partners. Its lead product, motixafortide, is marketed in the United States as Aphexda. The FDA approved Aphexda, in combination with filgrastim, to mobilize hematopoietic stem cells for collection in adults with multiple myeloma who are preparing for autologous transplantation. BioLineRx has also studied motixafortide in clinical trials for conditions including pancreatic cancer. BioLineRx’s activities span Israel and international markets, with its research and clinical programs involving partners and trial sites in multiple countries. The company continues to develop additional drug candidates and investigate potential uses for motixafortide.AI Generated. May Contain Errors. Read More BioLineRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreBLRX MarketRank™: 0.579931071045 of 5 starsBioLineRx scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBioLineRx has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBioLineRx has only been the subject of 1 research reports in the past 90 days.Read more about BioLineRx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioLineRx are expected to grow in the coming year, from ($1.57) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLineRx is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLineRx is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLineRx has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioLineRx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.77% of the float of BioLineRx has been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 17.18, which indicates bearish sentiment.Change versus previous monthShort interest in BioLineRx has recently decreased by 0.28%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioLineRx does not currently pay a dividend.Dividend GrowthBioLineRx does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.60 News SentimentBioLineRx has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BioLineRx this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioLineRx insiders have not sold or bought any company stock.Percentage Held by Insiders1.10% of the stock of BioLineRx is held by insiders.Percentage Held by Institutions1.56% of the stock of BioLineRx is held by institutions.Read more about BioLineRx's insider trading history. Receive BLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BLRX Stock News HeadlinesBioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026November 16 at 7:00 AM | prnewswire.comBioLineRx (BLRX) Set to Release Quarterly Earnings on MondayNovember 16 at 2:27 AM | americanbankingnews.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 17 at 1:00 AM | Behind the Markets (Ad)BioLineRx Ltd. And Hemispherian AS Present Preclinical Data Demonstrating Synergy Of GLIX1 With PARP Inhibitors In HR-Proficient Ovarian Cancer At ESMO 2026October 23, 2026 | marketscreener.comMBioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026October 23, 2026 | prnewswire.comBioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education DayOctober 8, 2026 | prnewswire.comBioLineRx Shareholders Approve Board, Capital and Compensation Moves at 2026 AGMSeptember 24, 2026 | tipranks.comBioLineRx And Hemispherian To Present GLIX1 Data At EANO 2026; Stock UpSeptember 10, 2026 | rttnews.comSee More Headlines BLRX Stock Analysis - Frequently Asked Questions How have BLRX shares performed this year? BioLineRx's stock was trading at $2.77 on January 1st, 2026. Since then, BLRX shares have decreased by 56.7% and is now trading at $1.20. How were BioLineRx's earnings last quarter? BioLineRx Ltd. (NASDAQ:BLRX) announced its quarterly earnings results on Friday, August, 28th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.62. The biotechnology company earned $294 thousand during the quarter, compared to analyst estimates of $500 thousand. BioLineRx had a negative net margin of 502.08% and a negative trailing twelve-month return on equity of 34.80%. Read the conference call transcript. When did BioLineRx's stock split? BioLineRx's stock reverse split before market open on Thursday, January 30th 2025.The 1-40 reverse split was announced on Friday, January 17th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of BioLineRx? Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioLineRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include NVIDIA (NVDA), Tesla (TSLA), Viking Therapeutics (VKTX), Tonix Pharmaceuticals (TNXP), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and SCYNEXIS (SCYX). Company Calendar Last Earnings8/28/2026Today11/17/2026Next Earnings (Estimated)11/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BLRX's financial health is in the Red zone, according to TradeSmith. BLRX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BLRX CIK1498403 Webwww.biolinerx.com Phone(728) 642-9100Fax972-8642-9101Employees22Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.17 million Net Margins-502.08% Pretax Margin-728.45% Return on Equity-34.80% Return on Assets-18.27% Debt Debt-to-Equity Ratio0.13 Current Ratio1.20 Quick Ratio1.04 Sales & Book Value Annual Sales$1.18 million Price / Sales4.87 Cash FlowN/A Price / Cash FlowN/A Book Value$5.36 per share Price / Book0.22Miscellaneous Outstanding Shares4,980,000Free Float4,923,000Market Cap$5.75 million OptionableOptionable Beta1.64 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:BLRX) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBitcoin's problem is its own sizeBitcoin is trading near $60,000. For your Bitcoin position to double from here, roughly $1.5 trillion in new m...Crypto 101 Media | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.